Home > Pulmonology > ERS 2022 > Favipiravir may help younger patients with COVID-19 recover

Favipiravir may help younger patients with COVID-19 recover

Presented By
Dr Christopher Orton, Royal Brompton Hospital, UK
Conference
ERS 2022
Trial
Phase 3, PIONEER
Although early intervention with favipiravir did not improve clinical outcomes for the overall population of hospitalised patients with COVID-19, a phase 3 study displayed that the agent may induce health benefits for patients under 60 years of age. “Re-using existing agents for a different purpose is faster than developing novel drugs,” argued Dr Christopher Orton (Royal Brompton Hospital, UK). Following this rationale, the phase 3 PIONEER trial (NCT04373733) was designed to test favipiravir, a medicine that demonstrated activity against various RNA viruses, in individuals with COVID-19 (n=503). Patients who were hospitalised due to COVID-19 were randomised 1:1 to receive a 10-day treatment with favipiravir or placebo. The primary objective of the trial was to assess whether early intervention with favipiravir reduced the time to significant improvement in the hea...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on